CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

Xu, Duo; Shun-Qing, Liang; Yang, Haitang; Bruggmann, Rémy; Berezowska, Sabina; Zhang, Yang; Marti, Thomas; Hall, Sean Ralph Robert; Gao, Yanyun; Kocher, Gregor J.; Schmid, Ralph A.; Peng, Ren-Wang (2020). CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma. Molecular cancer therapeutics, 19(2), pp. 661-672. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-19-0724

Full text not available from this repository.

Malignant pleural mesothelioma (MPM) is an aggressive cancer with dismal prognosis, largely due to poor response rates to and rapid relapse after first-line pemetrexed (MTA)/cisplatin chemotherapy. A better understanding of the molecular mechanisms underlying chemotherapy sensitivity and duration represents a significant but still unmet clinical need. In this study, we reported on a kinome CRISPR/Cas9 knockout screen that identified several G2-M checkpoint kinases, including WEE1, whose loss of function sensitizes MPM cells to standard chemotherapy. We further showed that deregulation of the G2-M checkpoint contributes to chemotherapy resistance, and that WEE1 inhibition synergizes with cisplatin/MTA, leading to enhanced MPM cell death in vitro and potent anti-tumor effects in vivo. Mechanistically, WEE1 blockage overrides chemotherapy-induced G2-M cell cycle arrest and promotes premature mitotic entry, which causes DNA damage accumulation and ultimately apoptosis. Our results suggest a new therapeutic combination for MPM, and support the application of CRISPR/Cas9-based functional genomics in identifying novel therapeutic targets to potentiate existing cancer therapies.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery 04 Faculty of Medicine > Faculty Institutions > Teaching Staff, Faculty of Medicine 04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DCR Services > Core Facility Zytometrie-Labor/FACSlab 04 Faculty of Medicine > Service Sector > Institute of Pathology > Translational Research Unit 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DCR Services > Core Facility Live Cell Imaging (LCI) 08 Faculty of Science > Department of Biology > Bioinformatics and Computational Biology
Graduate School:	Graduate School for Cellular and Biomedical Sciences (GCB)
UniBE Contributor:	Xu, Duo, Shun-Qing, Liang, Yang, Haitang, Bruggmann, Rémy, Berezowska, Sabina Anna, Yang, Zhang (A), Marti, Thomas, Hall, Sean, Gao, Yanyun, Kocher, Gregor, Schmid, Ralph, Peng, Ren-Wang
Subjects:	600 Technology > 610 Medicine & health 500 Science > 570 Life sciences; biology
ISSN:	1535-7163
Publisher:	American Association for Cancer Research AACR
Language:	English
Submitter:	Thomas Michael Marti
Date Deposited:	21 Nov 2019 13:22
Last Modified:	05 Dec 2022 15:32
Publisher DOI:	10.1158/1535-7163.MCT-19-0724
PubMed ID:	31694888
URI:	https://boris.unibe.ch/id/eprint/135013